OptimizeRx (NASDAQ:OPRX) Stock Keeps Buy Rating at B. Riley Financial

Key Points

• B. Riley reaffirmed its Buy rating on OptimizeRx but lowered its price target to $10.50 from $11.00; that target implies 58.16% upside from the prior close.
• OptimizeRx shares fell 25.8% to $6.64 on Thursday. The analyst consensus remains “Moderate Buy,” with an average price target of $11.36.
• Quarterly results topped estimates: EPS was $0.20 versus $0.16 expected, and revenue was $21.61 million versus $21.19 million. However, the company’s fiscal 2026 revenue guidance of $87 million–$93 million was below the $96.2 million analyst consensus.

OptimizeRx (NASDAQ:OPRX - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at B. Riley Financial in a report released on Thursday, Benzinga reports. They currently have a $10.50 price objective on the stock, down from their previous price objective of $11.00. B. Riley Financial's price objective indicates a potential upside of 58.16% from the stock's previous close.

A number of other brokerages have also commented on OPRX. Stifel Nicolaus dropped their price target on OptimizeRx from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Thursday. Citizens Jmp increased their price target on shares of OptimizeRx from $9.00 to $11.00 and gave the company a "market outperform" rating in a research report on Friday, August 14th. Wall Street Zen downgraded shares of OptimizeRx from a "strong-buy" rating to a "buy" rating in a research report on Monday, July 20th. UBS Group set a $11.00 target price on shares of OptimizeRx in a research report on Friday, August 14th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of OptimizeRx in a report on Tuesday, October 27th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $11.36.

OptimizeRx Stock Down 25.8%

OPRX stock traded down $2.31 during trading on Thursday, reaching $6.64. The stock had a trading volume of 344,001 shares, compared to its average volume of 349,433. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $125.08 million, a price-to-earnings ratio of 28.98 and a beta of 1.20. OptimizeRx has a one year low of $4.54 and a one year high of $16.37. The company's 50 day moving average is $8.43 and its two-hundred day moving average is $7.24.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its earnings results on Wednesday, November 11th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.16 by $0.04. The firm had revenue of $21.61 million for the quarter, compared to analysts' expectations of $21.19 million. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. Equities research analysts forecast that OptimizeRx will post 0.49 EPS for the current year.

Institutional Trading of OptimizeRx

A number of hedge funds and other institutional investors have recently made changes to their positions in OPRX. Corient Private Wealth LP bought a new position in OptimizeRx in the 2nd quarter worth about $77,000. Hsbc Holdings PLC purchased a new position in shares of OptimizeRx in the 1st quarter worth about $85,000. Cetera Investment Advisers bought a new position in OptimizeRx during the first quarter valued at approximately $173,000. State of Wyoming raised its position in OptimizeRx by 234.6% in the 1st quarter. State of Wyoming now owns 35,251 shares of the company's stock worth $221,000 after purchasing an additional 24,716 shares during the period. Finally, Quantinno Capital Management LP increased its holdings in shares of OptimizeRx by 180.1% in the first quarter. Quantinno Capital Management LP now owns 49,022 shares of the company's stock worth $308,000 after buying an additional 31,518 shares during the period. 76.47% of the stock is currently owned by institutional investors.

Recent OptimizeRx Headlines

These are some of the OPRX headlines that stood out recently:

• Positive Sentiment: Q3 2026 adjusted earnings were $0.20 per share, above estimates of $0.16–$0.18. Revenue of about $21.6 million also topped the $21.19 million consensus. Zacks Q3 earnings report
• Neutral Sentiment: Stifel Nicolaus lowered its price target from $12 to $11 but maintained its Buy rating. The target cut is a cautionary signal, though the firm remains positive on the shares. Stifel Nicolaus recommendations
• Negative Sentiment: OptimizeRx guided to FY 2026 revenue of $87 million–$93 million, below the $96.2 million analyst consensus. This weaker-than-expected outlook could overshadow the quarterly beat. Company results and guidance

About OptimizeRx

OptimizeRx Corporation NASDAQ: OPRX is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey. The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.